Evidence map›Paper›PMID 35626146›Full record

ArticleCancers2022

Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature.

Rafael Stroggilos, Maria Frantzi, Jerome Zoidakis, Marika Mokou, Napoleon Moulavasilis, Emmanouil Mavrogeorgis, Anna Melidi, Manousos Makridakis, Konstantinos Stravodimos, Maria G Roubelakis and 2 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Repurposing Amiodarone for Bladder Cancer Treatment.Cancer research communications · 2025
    Article
  3. Article
  4. Role of ENO1 and its targeted therapy in tumors.Journal of translational medicine · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rafael StroggilosSystems Biology Center, Biomedical Research Foundation of the Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.ORCID 0000-0003-4068-9167
Maria FrantziMosaiques Diagnostics GmbH, 30659 Hannover, Germany.ORCID 0000-0003-0415-0316
Jerome ZoidakisSystems Biology Center, Biomedical Research Foundation of the Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.ORCID 0000-0002-4557-3430
Marika MokouMosaiques Diagnostics GmbH, 30659 Hannover, Germany.ORCID 0000-0002-4511-1578
Napoleon Moulavasilis1st Department of Urology, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Emmanouil MavrogeorgisSystems Biology Center, Biomedical Research Foundation of the Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.
Anna MelidiSystems Biology Center, Biomedical Research Foundation of the Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.
Manousos MakridakisSystems Biology Center, Biomedical Research Foundation of the Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.ORCID 0000-0002-0063-3559
Konstantinos Stravodimos1st Department of Urology, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Maria G RoubelakisLaboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Harald MischakMosaiques Diagnostics GmbH, 30659 Hannover, Germany.ORCID 0000-0003-0323-0306
Antonia VlahouSystems Biology Center, Biomedical Research Foundation of the Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.ORCID 0000-0003-3284-5713

Funding

European Union's Horizon-2020 Marie Sklodowska-Curie 860329European Union's Horizon-2020 Marie Sklodowska-Curie 898260
6 · The paper itself

Abstract

Despite advancements in molecular classification, tumor stage and grade still remain the most relevant prognosticators used by clinicians to decide on patient management. Here, we leverage publicly available data to characterize bladder cancer (BLCA)'s stage biology based on increased sample sizes, identify potential therapeutic targets, and extract putative biomarkers. A total of 1135 primary BLCA transcriptomes from 12 microarray studies were compiled in a meta-cohort and analyzed for monotonal alterations in pathway activities, gene expression, and co-expression patterns with increasing stage (Ta-T1-T2-T3-T4), starting from the non-malignant tumor-adjacent urothelium. The TCGA-2017 and IMvigor-210 RNA-Seq data were used to validate our findings. Wnt, MTORC1 signaling, and MYC activity were monotonically increased with increasing stage, while an opposite trend was detected for the catabolism of fatty acids, circadian clock genes, and the metabolism of heme. Co-expression network analysis highlighted stage- and cell-type-specific genes of potentially synergistic therapeutic value. An eight-gene signature, consisting of the genes

Indexed as

bladder cancer stagemeta-analysismolecular alterationsprognostic signaturetranscriptomicsurothelial carcinoma

Identifiers

PMID35626146
PMCPMC9140126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.